A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumoursNicola Steele, Johann S. de Bono, J A Evans et al.|Journal of Clinical Oncology|2005Cited by 19